Baidu
map

Oncogene:雌激素受体β能够促进肾细胞恶性肿瘤的恶化

2018-06-03 AlexYang MedSci原创

之前的研究表明了雌激素受体β(ERβ)能够影响前列腺肿瘤和膀胱肿瘤的恶化,然而,它在肾细胞恶性肿瘤(RCC)中的作用仍旧处于待阐释状态。最近,有研究人员阐释了在RCC患者中,雌激素受体β的表达与总生存/无疾病生存具有负相关关系,并且还提供了相关临床证据。研究人员对机制的剖析阐释了利用雌激素受体β-shRNA以雌激素受体β为靶标和利用17β-雌二醇或者环境内分泌干扰物刺激雌激素受体β的反式激活,均能

之前的研究表明了雌激素受体β(ERβ)能够影响前列腺肿瘤和膀胱肿瘤的恶化,然而,它在肾细胞恶性肿瘤(RCC)中的作用仍旧处于待阐释状态。

最近,有研究人员阐释了在RCC患者中,雌激素受体β的表达与总生存/无疾病生存具有负相关关系,并且还提供了相关临床证据。研究人员对机制的剖析阐释了利用雌激素受体β-shRNA以雌激素受体β为靶标和利用17β-雌二醇或者环境内分泌干扰物刺激雌激素受体β的反式激活,均能够导致lncRNA HOTAIR表达的改变。另外,雌激素受体β调节的HOTAIR可通过中和一些microRNAs来发挥其功能,这些微小RNA包括了miR-138, miR-200c, miR-204或者 miR-217,从而来影响各种致瘤基因的功能,包括ADAM9, CCND2, EZH2, VEGFA, VIM, ZEB1和ZEB2,促进RCC的扩增侵入。

最后,研究人员之指出,ERβ-HOTAIR通路的鉴定能够为未来更好的抑制RCC的恶化提供新的生物标记或者治疗靶标。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049036, encodeId=0af020490365c, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jun 06 11:52:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503488, encodeId=2610150348837, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Tue Jun 05 09:52:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558118, encodeId=4d541558118b4, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Jun 05 09:52:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321401, encodeId=14f7321401f9, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Jun 04 09:39:13 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321361, encodeId=c06532136171, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Jun 04 07:57:33 CST 2018, time=2018-06-04, status=1, ipAttribution=)]
    2018-06-06 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=2049036, encodeId=0af020490365c, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jun 06 11:52:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503488, encodeId=2610150348837, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Tue Jun 05 09:52:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558118, encodeId=4d541558118b4, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Jun 05 09:52:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321401, encodeId=14f7321401f9, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Jun 04 09:39:13 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321361, encodeId=c06532136171, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Jun 04 07:57:33 CST 2018, time=2018-06-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2049036, encodeId=0af020490365c, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jun 06 11:52:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503488, encodeId=2610150348837, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Tue Jun 05 09:52:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558118, encodeId=4d541558118b4, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Jun 05 09:52:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321401, encodeId=14f7321401f9, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Jun 04 09:39:13 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321361, encodeId=c06532136171, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Jun 04 07:57:33 CST 2018, time=2018-06-04, status=1, ipAttribution=)]
    2018-06-05 zsyan
  4. [GetPortalCommentsPageByObjectIdResponse(id=2049036, encodeId=0af020490365c, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jun 06 11:52:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503488, encodeId=2610150348837, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Tue Jun 05 09:52:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558118, encodeId=4d541558118b4, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Jun 05 09:52:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321401, encodeId=14f7321401f9, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Jun 04 09:39:13 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321361, encodeId=c06532136171, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Jun 04 07:57:33 CST 2018, time=2018-06-04, status=1, ipAttribution=)]
    2018-06-04 一个字-牛

    学习了谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2049036, encodeId=0af020490365c, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Jun 06 11:52:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503488, encodeId=2610150348837, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Tue Jun 05 09:52:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558118, encodeId=4d541558118b4, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Jun 05 09:52:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321401, encodeId=14f7321401f9, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Jun 04 09:39:13 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321361, encodeId=c06532136171, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Jun 04 07:57:33 CST 2018, time=2018-06-04, status=1, ipAttribution=)]
    2018-06-04 kafei

    学习了谢谢

    0

相关资讯

理想照进现实:氟维司群进入国家医保目录,惠及更多ER+晚期乳腺癌患者

2017年7月,国家医保目录更新,氟维司群作为唯一一个乳腺癌内分泌治疗药物,也是目前最有效的内分泌治疗药物被纳入国家医保乙类目录。在未来,氟维司群会为更多的ER+晚期乳腺癌患者带来福音。

Science:雌激素受体(ER)阳性乳腺癌抵抗PI3K抑制剂疗法的原因

KMT2D甲基转移酶原本受到PI3K信号通路中的AKT蛋白的抑制,当使用PI3K抑制剂后,AKT的活性下降,从而使KMT2D甲基转移酶的功能上升

Sci Rep:肝雌激素受体α对于调节男性的糖原异常和脂质代谢至关重要!

在动物模型和人类中,雌激素的作用受损与代谢综合征的特征密切相关。近期,一项发表在杂志Sci Rep上的研究旨在评估成年雄性小鼠中,肝脏雌激素作用的破坏是否可以重述代谢综合征的相关表现,以了解表型的基础机制。研究者们发现,17β-雌二醇(E2)抑制肝糖异生基因如磷酸烯醇丙酮酸羧激酶1(Pck-1)和葡萄糖-6-磷酸酶(G6Pase),并且在缺乏肝雌激素受体α(Esr1)(LERKO小鼠)的小鼠中不存

Radiology:雌激素受体阳性乳腺癌复发风险?定性放射基因学组来说道说道!

乳腺癌Breast Cancer是目前全球女性中发病最高的恶性肿瘤,是一种全身性疾病,乳腺位置及乳腺癌示意图在早期即可发生腋淋巴结转移,因此在治疗策略上早期发现并阻断其转移对乳腺癌的治疗及预后具有重大的临床意义。而浸润性乳腺癌是乳腺癌的主要类型严重危害着女性的身心健康。本研究旨在评价雌激素受体阳性乳腺癌患者乳腺影像学报告和数据系统(BI-RADS)乳腺X线摄影和磁共振(MR)成像特征与乳腺复发风险

Cell Reports:雌激素受体对男性前列腺很重要!

近日,来自美国的科学家在国际学术期刊Cell Reports在线发表了他们的最新研究进展,他们发现在PTEN缺失诱导的前列腺癌发生过程中,雌激素受体β(ERβ)的表达受到抑制,对于前列腺癌发生起到重要推动作用。   雌激素受体(ER)在上皮细胞生物学和癌症中的作用越来越得到关注,在前列腺中,ERβ表达在上皮细胞,而ERα只限于基底层细胞。虽然之前一些研究表明ERβ缺失与恶性疾病有关,

Cancer Res:重大突破!特殊蛋白或可恢复耐受性乳腺癌对常见疗法的敏感性

乳腺癌是一种常见的女性癌症,而且雌激素受体阳性(ER+)的乳腺癌是一种最为常见的乳腺癌类型,目前用于治疗乳腺癌的药物,比如他莫昔芬和氟维司群都能够阻断雌激素受体,而雌激素受体是雌激素受体阳性的乳腺癌细胞生长所必需的受体,这些疗法治疗乳腺癌的常见问题就是许多最初对疗法有反应的肿瘤会慢慢产生耐受性,从而使得疗法变得不再有效。日前,一项刊登在国际杂志Cancer Research上的研究报告中,来自美国

Baidu
map
Baidu
map
Baidu
map